Polymorphisms in the CHRNA4 gene coding the nicotinic acetylcholine receptor subunit a4 have recently been suggested to play a role in the determination of smoking-related phenotypes. To examine this hypothesis, we conducted a genetic association study in three large samples from the German general population (N 1 ¼ 1412; N 2 ¼ 1855; N 3 ¼ 2294). Five singlenucleotide polymorphisms in CHRNA4 were genotyped in 5561 participants, including 2707 heavily smoking cases (regularly smoking at least 20 cigarettes per day) and 2399 never-smoking controls (p100 cigarettes over lifetime). We examined associations of the polymorphisms with smoking case-control status and with the extent of nicotine dependence as measured by the Fagerstrom test of nicotine dependence (FTND) score (N ¼ 1030). The most significant association was observed between rs2236196 and FTND (P ¼ 0.0023), whereas the closely linked rs1044396 had most statistical support in the case-control models (P ¼ 0.0080). The consistent effect estimates across three independent cohorts elaborate on recently published functional studies of rs2236196 from the CHRNA4 3 0 -untranslated region and seem to converge with accumulating evidence to firmly implicate the variant G allele of this polymorphism in the intensification of nicotine dependence.
Introduction
Smoking remains a major cause of morbidity and premature death. 1 The addictive potential of the nicotine contained in cigarettes has been firmly established, 2 but individual and especially genetic differences regarding susceptibility to nicotine addiction, which could give crucial hints to drug discovery, are not well understood. 3 Nicotinic acetylcholine receptor subunit genes are obvious candidates for genetic risk factor investigations into smoking-related traits, for example see Hoft et al. 4 The a4-subunit of the pentameric nicotinic receptor, which is especially frequent as part of high-affinity receptors in the central nervous system, 5 has yielded particularly interesting results in the few studies available to date. Single-nucleotide polymorphisms (SNPs) or haplotypes of the coding gene CHRNA4 have been implicated as predictors of nicotine addiction in family-based analyses 6, 7 and have been reported to be associated with smoking cessation in a clinical trial. 8 The pathophysiological importance of SNPs in CHRNA4 has furthermore been supported by functional magnetic resonance imaging studies relating the CHRNA4 SNP rs1044396 to attentional network function, which is believed to be a key component of nicotine addiction at least in a subgroup of smokers. 9 To further elucidate the role of genetic variants of the a4-subunit of nicotinic acetylcholine receptors in nicotine addiction, we embarked on a large association study of SNPs in CHRNA4 with smoking status, extent of nicotine dependence and smoking cessation probability in more than 5500 participants recruited from the general population in Germany.
Results
A total of 5561 subjects with a mean (range) age of 51.8 years contributed to the analyses presented here, of whom 3605 (65%) were men. Participants included 3134 regularly smoking cases, of whom 2707 qualified as heavy smokers, and 2399 never-smoking controls. Observed genotype distributions generally were consistent with published data (CEPH or HapMap-CEU populations as provided by SNPdb (http://www.ncbi.nlm.nih.gov/SNP)). Detailed characteristics of the subcohorts R1-R3 are provided in Table 1 , genotype information, Hardy-Weinberg equilibrium (HWE) P-values and quality criteria in Table 2 . Supplementary Figure 1 provides linkage disequilibrium (D 0 and r 2 ) plots produced based on the combined data set. The main results are presented in Table 3 . For the intronic rs2273504 typed in R1 and R2, relevant associations This was motivated by technical reasons, effect estimates for rs2229959 being rather imprecise due to relatively low minor allele frequency, and coincided with new evidence suggesting an association of rs1044396 with attentional network function implicated in addictive smoking. 9 Indeed, the extent of nicotine dependence appeared to increase with the number of rs1044396 variant alleles ( Table 3) or those of the closely linked rs1044397 (R2:
Similar to rs2236196, the casecontrol estimates within individual samples had corresponding confidence intervals just including the Null effect of no association, but the estimates were in the same direction in all three cohorts, and in particular in R2 and R3 were of very similar magnitude. The resulting combined estimates consequently were highly significant, despite none of the combined effect sizes exceeding OR ¼ 1.14. Though based on the smallest sample size, the most significant association was observed for the 3 0 -untranslated region (3 0 UTR)-located rs2236196 with the Fagerstrom test of nicotine dependence (FTND) score (P ¼ 0.0023). The corresponding effect estimate of 0.075 translates into a 1.1-fold increase in nicotine dependence with each variant allele present. Results obtained when using a recessive rather than additive genotype model tended to show less significant associations, but generally were consistent with the additive model results (Supplementary Table S1 ).
In models exploring the associations separately for male and female participants, no consistent patterns emerged (Supplementary Tables S2 and S3 ). Fluctuations by sex appeared rather study specific, thus resembling chance variations somewhat expected due to reduced numbers of subjects contributing to each stratified model. This was also underlined by wide confidence intervals. In contrast, the combined effect estimates altogether were consistent with no important effect heterogeneity by sex being present. Sexstratified analyses of FTND are not presented due to the prohibitively small number of subjects with FTND data.
For R3 cases, information on the life history of smoking had also been obtained by self-administered standardized questionnaire (items asking for age at smoking initiation and cessation, smoking quantity at enrollment and ages 20, 30, 40 and 50 years), and the association of the SNPs with the time from smoking initiation to smoking cessation was examined by Cox proportional hazards modeling. The estimated effects generally were not significant and no trend was apparent ( Table 4 ). The sex-stratified models again suffered from smaller numbers of subjects contributing. Nonetheless, the most pronounced deviation from the Null effect (a trend toward decreasing cessation probability with Table 3 Association of CHRNA4 SNPs with smoking-related phenotypes; additive genotype models adjusted for age and sex
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Reference/ variant allele CHRNA4 and smoking LP Breitling et al more rs2236196 G alleles in women) was consistent with the main analyses (Table 3) , in which this allele appeared associated with higher probability of nicotine addiction and with an increase in nicotine dependence as measured by FTND scores. Including adjustments for various established predictors of smoking cessation (sex and education, or concurrent smoking intensity) resulted in only small changes in effect estimates, which were in varying directions and yielded no additional insight (not shown).
Discussion
In this large-scale genetic study, we observed significant associations of the functional 3 0 UTR polymorphism rs2236196 and two closely linked exon 5 variations (rs1044396 and rs1044397) with the extent of nicotine dependence as measured by FTND or the probability of being a regular and/or heavy smoker.
Coding part of the high-affinity nicotinic acetylcholine receptor consisting of a4-and b2-subunits, CHRNA4 has received quite some attention in genetic studies on nicotine dependence. Closer examination of the published evidence reveals a not entirely consistent picture. For example, although two studies reported evidence for CHRNA4 haplotypes being associated with measures of nicotine dependence, the respective protective haplotypes featured opposing alleles at the rs2236196 locus. 6, 7 Although the rs2273504 SNP appeared in both protective haplotypes in a consistent manner, it was individually significant only in ethnic-specific subanalyses, 7 but neither in the other study nor in ours. In contrast, either rs2236196 or one of the nearby exon 5 SNPs emerged as most strongly associated with the various phenotypes. The associations observed for the two significant exon 5 SNPs could plausibly be explained by tight linkage disequilibrium with the functional rs2236196 (D 0 ¼ 0.98 and r 2 ¼ 0.41 for both rs1044396 and rs1044397 in R3). This would be consistent with rs2236196 being the best CHRNA4 predictor in another large candidate gene study, 10 as well as with the results presented above. The T allele of this SNP has recently been found to roughly double the gene expression in luciferase activity assays. 8 Additional findings on clinical effects furthermore suggested that C alleles render subjects more sensitive to acute effects of nicotine. With the equivalent allele (G) being associated with higher intensity of nicotine dependence and higher odds of being a smoker in our study, the evidence appears to be converging on a truly causal association between rs2236196 and nicotine-related phenotypes, though additional replications in independent study samples and other ethnic groups should be awaited before drawing definite conclusions. To this end, it should be noted that more detailed examination of a previous larger study 10 revealed that the effect for rs2236196 in this study actually was consistent in size and direction with our findings (http:// zork.wustl.edu/nida/Results/cg_snps.xls; accessed on 29 July 2008).
Some very recent large-scale studies have identified other nicotinic acetylcholine receptor subunit genes rather than Results of Cox proportional hazards models regressing the time from smoking initiation to cessation on individual SNPs based on categorical or additive genetic models. a HR, hazard ratio; here to be interpreted as the relative rate of smoking cessation in reference to subjects homozygous for the major allele. No individual effect estimate was significant based on an uncorrected Po0.05.
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CHRNA4 as most significant determinants of a variety of smoking phenotypes, both on a genome-wide basis 11, 12 or in candidate gene approaches where CHRNA4 SNPs were not found to be significant. 13 With accumulating data, appropriate meta-analytic studies will allow a more definite assessment of the CHRNA4-smoking association in the relatively near future.
The study presented here had a large sample size, allowing rather precise effect estimation, and the genotyping in three independent samples allowed the replication of effect directions to emerge as additional support for the validity of our results. Still, due to the small effects often encountered in the genetic epidemiology of complex diseases, the number of participants preferably should be further increased in future studies. A major strength of the study was that the selection of the candidate gene was informed by multifaceted prior and emerging evidence. This not only yielded the ability to put the results into context with cutting edge functional and clinical knowledge added to the literature only very recently, but also increased the a priori probability of our positive findings presenting true associations.
In conclusion, the associations reported here between a functional SNP in the CHRNA4 gene or closely linked genetic loci and the risk of nicotine dependence as measured by FTND or being a regular and/or heavy smoker contribute to accumulating evidence obtained through diverse methods firmly implicating CHRNA4 in the development or maintenance of nicotine dependence. As variations in this gene also appear to have a function in numerous neuropsychiatric disorders and in the attentional network function known to correlate with cigarette smoking and nicotine dependence, 9 future large studies should aim not only to reproduce the findings reported to date, but also incorporate detailed endophenotypic assessments in an attempt to elucidate causal pathways leading from SNPs to smoking. Such endophenotypic analyses of subcohorts of the present study are ongoing.
Materials and methods
Polymorphisms covering CHRNA4 from intron 2 to the 3 0 UTR were selected based on literature search and prior research results as suitable candidate determinants of nicotine addiction-related phenotypes. Corresponding SNPs (rs2273504, rs2229959, rs1044397 and rs2236196) were genotyped in up to three consecutive rounds (R1-R3) in general population-based samples of various studies collaborating in an effort to elucidate genetic determinants of smoking-related phenotypes. Individual candidate SNPs for the present analyses were heuristically carried forward to the next round of genotyping based on the findings in the preceding samples and prior evidence.
In brief, the first replication sample (R1) consisted of 1412 participants of the MONICA/KORA Augsburg study, surveys S3/F3 (1994/1995 and 10 years later) and S4 (1999/2001) . The 1412 R1 subjects were selected randomly from the overall 9117 participants of S3 and S4, independent samples drawn from the population aged 25-84 years living in the southern German study region. Pertinent study procedures have been described previously. 14, 15 The second replication sample (R2) analyses included 1855 participants of various cooperating studies on nicotine addiction (NCOOP) conducted in Germany and including smoking characterization along with DNA acquisition. The study centers were at the Ludwig Maximilians University of Munich, the German Cancer Research Center Heidelberg, the University of Mainz, the University of Düsseldorf and the University of Berlin.
The third replication sample (R3) was based on the ESTHER cohort study conducted in the state of Saarland, where 9953 subjects aged 50-74 years were recruited during health screening examinations by their general practitioner. 16, 17 For the present analyses, only subjects reporting regularly smoking more than 20 cigarettes daily at some point during their life were included as cases, along with never-smoking controls randomly selected from the overall cohort (frequency matched by 5-year age groups and sex). 1525 ever-smokers and 769 controls ultimately contributed to this study.
Ethical approval from the appropriate institutions was obtained in the context of the individual studies contributing. The analyses presented in this report were covered by the ethical approvals and written informed consent was required for study participation throughout.
Primary phenotypes examined were smoking case status ('regular smoker' defined as regularly smoking at least 1 cigarette daily, or 'heavy smoker' defined as smoking at least 20 cigarettes daily, in reference to 'never smoker' defined as having smoked a maximum of 100 cigarettes over lifetime) and the score of the FTND, 18 which was available for a subset of R1 and R2 subjects. In R3, only heavy smokers were included as cases. Considering ever-reaching regular heavy smoking to indicate having developed nicotine dependence, the latter were all treated as regular and heavy smokers, although many had already quit smoking at study enrollment. Time from smoking initiation to cessation was examined as an additional phenotype in retrospective cohort analyses restricted to R3 cases.
For the purpose of genotyping, DNA was obtained from peripheral blood by methods varying by study. Genotyping platforms employed were Illumina BeadStation 500G Sentrix Array Matrices (Illumina, San Diego, CA, USA) for R1 and iPLEX matrix-assisted laser desorption-ionization timeof-flight mass spectrometry (Sequenom, San Diego, CA, USA) for R2 and R3. To ensure the validity of results, we performed genotyping by personnel unaware of the phenotypic data and included 10% duplicate samples (discordance rate cutoff 0.3%), negative and positive controls, sex-control SNPs and exact testing whether genotype distributions diverged from HWE. Two SNPs (rs2229959 and rs1044397) analyzed for this paper first did not pass quality control in the R1 cohort, but subsequently could successfully be re-genotyped resulting in conformity with our stringent quality control criteria. HWE testing was conducted in controls, because only subjects fulfilling case or control definitions were included in our study.
Logistic and quasi-Poisson regression models adjusted for age and sex (or stratified on the latter) were employed to examine associations of individual SNPs with smoking status and FTND score, respectively. In the FTND data, the basic assumption of the Poisson model, which is that the variance equals the expectation, was not fulfilled. The quasiPoisson model we employed instead allows for differing dispersion parameters and can therefore correct for this socalled overdispersion. It is more conservative than the Poisson model and, if no overdispersion is present, leads to the same results. Both additive and recessive genetic models were evaluated. The main analyses were carried out using R 2.6.0 19 and the extension package 'genetics'. SAS 9.1 20 was used to obtain combined effect estimates from a fixed effects model with inverse variance weights (heterogeneity of the effect estimates was judged insignificant by Qtest for all models presented), as well as for the Cox proportional hazards modeling in retrospective cohort analyses restricted to R3 cases. Haplotype analyses were not conducted because resource constraints did not allow us to genotype the same SNPs in all three samples. The number of effective independent loci was estimated for all three samples combined, 21 indicating that P-values of 0.05/ 4 ¼ 0.0125 should be considered significant to maintain the usual a level of 0.05.
